Drug
SCH 727965
SCH 727965 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
NCT00871910
terminatedphase_2
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
NCT00871546
completedphase_2
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
NCT00732810
completedphase_1
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
NCT00871663
terminatedphase_2
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
NCT00798213
Clinical Trials (5)
Showing 5 of 5 trials
NCT00871910Phase 1
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
NCT00871546Phase 2
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
NCT00732810Phase 2
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
NCT00871663Phase 1
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
NCT00798213Phase 2
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5